Support teaching, research, and patient care.
A board-certified internist and fellowship-trained nephrologist, Dr. Tan is currently medical director of the Adult Kidney and Pancreas Transplant Program at Stanford Health Care. She is a professor of medicine at Stanford University in the Department of Medicine, Division of Nephrology, where she has been a faculty member since 2000.Dr. Tan’s clinical work and research focuses on frailty and access to kidney transplants. She led the creation and use of the Transplant and Readiness Assessment Clinic at Stanford Health Care. Through this clinic, Dr. Tan provides transplant opportunities for aging patients or those with complex medical conditions that may otherwise encounter barriers to transplant. This work led to dramatic increases in transplant volumes while maintaining excellent clinical outcomes.Dr. Tan has published research in numerous academic journals. Her studies in living donor physiology have led to better education and improved counseling in donor selection and follow-up, while her investigation of aging kidneys has led to wider and more judicious use of older donor organs for transplantation. She is the associate editor of the American Journal of Transplantation and kidney transplant section editor for UpToDate®, a leading online clinical decision support tool.Dr. Tan received her bachelor and master of science degrees in biomedical engineering from Johns Hopkins University. She received her medical and doctor of philosophy degrees from the University of Rochester School of Medicine and Dentistry in Rochester, New York. She then completed her residency and fellowship at Beth Israel Deaconess Medical Center, a teaching affiliate of Harvard Medical School. She is a fellow of the American Society of Transplantation and served on committees and advisory boards including the American Society of Transplantation and American Society of Nephrology.
My research relates to issues pertaining to clinical kidney transplantation. We have ongoing studies on the following topics.1. Renal senescence and kidney transplant, and chronic allograft nephropathy.2. Living donor safety and response to uninephrectomy.3. Biomarkers for post-transplant monitoring.
Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Protocol Title: Randomized open label study comparing the metabolic control of first Kidney
Transplant recipients with Type 2 Diabetes Mellitus (DM) receiving either Prograf or Neoral
as part of a ATG induction, prednisone free and blood monitored Cellcept immunosuppressive
PURPOSE This is a single center medical research study to analyze post-transplant kidney
recipients with pre-existing type 2 diabetes managed according to the recommended American
Diabetes Association (ADA) guidelines. Prograf (Tac) and Neoral (CSA) are the two main
medications to prevent rejection after transplantation. However, they may contribute to
poorer diabetes control. The purpose of the study is to compare the effects of Prograf and
Neoral on the control of Diabetes after kidney transplantation. In addition, all participants
in this study will receive Thymoglobulin (anti-lymphocyte globulin) at the time of
transplantation instead of long term prednisone (steroids).
Stanford is currently not accepting patients for this trial.
For more information, please contact Stephan Busque, MD, 650-498-6189.
View full details